Skip to content

Gene Biotherapeutics, Inc.: 10-K filed 2021-04-23

What Gene Biotherapeutics, Inc. reported in its annual report filed 2021-04-23 (fiscal FY 2019): 34 published measures, 239 facts as tagged in accession 0001493152-21-009535.

This filing

Form
10-K (annual report)
Filed
2021-04-23
Fiscal period
fiscal FY 2019
Accession
0001493152-21-009535 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All Gene Biotherapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-12-3135,435USD
At 2019-09-3067,009USD
At 2019-06-3041,791USD
At 2019-03-3162,938USD
At 2018-12-31161,895USD
At 2018-09-30276,475USD
At 2018-06-30140,481USD
At 2018-03-31120,783USD
At 2017-12-31209,773USD
At 2017-09-30170,390USD
At 2017-06-30220,359USD
At 2017-03-31373,928USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-12-314,885,198USD
At 2019-09-306,350,796USD
At 2019-06-306,175,121USD
At 2019-03-315,944,935USD
At 2018-12-315,790,786USD
At 2018-09-305,634,045USD
At 2018-06-305,861,727USD
At 2018-03-315,582,253USD
At 2017-12-315,365,920USD
At 2017-09-304,993,675USD
At 2017-06-304,624,785USD
At 2017-03-314,318,879USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-12-31-4,290,260USD
At 2018-12-31-5,156,935USD
At 2017-12-31-4,802,054USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-10-01 to 2019-12-311,450,080USD92
2019-01-01 to 2019-12-31866,675USD365
2019-07-01 to 2019-09-30-130,667USD92
2019-04-01 to 2019-06-30-226,369USD91
2019-01-01 to 2019-03-31-226,369USD90
2018-10-01 to 2018-12-31-242,052USD92
2018-01-01 to 2018-12-31-434,881USD365
2018-07-01 to 2018-09-30395,351USD92
2018-04-01 to 2018-06-30-312,207USD91
2018-01-01 to 2018-03-31-275,973USD90
2017-10-01 to 2017-12-31-521,204USD92
2017-01-01 to 2017-12-31-1,894,142USD365
2017-07-01 to 2017-09-30-375,322USD92
2017-04-01 to 2017-06-30-417,493USD91
2017-01-01 to 2017-03-31-580,123USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-12-31-137,162USD365
2018-01-01 to 2018-12-31-451,503USD365
2017-01-01 to 2017-12-31-1,062,388USD365

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-12-3155,447USD365
2018-01-01 to 2018-12-31-165,371USD365
2017-01-01 to 2017-12-31180,980USD365

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-01-01 to 2018-12-31650,000USD365

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-12-31-118,912,290USD
At 2018-12-31-119,778,965USD
At 2017-12-31-119,344,084USD

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2019-10-01 to 2019-12-310.1USD/shares92
2019-01-01 to 2019-12-310.05USD/shares365
2019-07-01 to 2019-09-30-0.01USD/shares92
2019-04-01 to 2019-06-30-0.02USD/shares91
2019-01-01 to 2019-03-31-0.02USD/shares90
2018-10-01 to 2018-12-31-0.02USD/shares92
2018-01-01 to 2018-12-31-0.03USD/shares365
2018-07-01 to 2018-09-300.03USD/shares92
2018-04-01 to 2018-06-30-0.02USD/shares91
2018-01-01 to 2018-03-31-0.02USD/shares90
2017-10-01 to 2017-12-31-0.04USD/shares92
2017-01-01 to 2017-12-31-0.13USD/shares365
2017-07-01 to 2017-09-30-0.03USD/shares92
2017-04-01 to 2017-06-30-0.02USD/shares91
2017-01-01 to 2017-03-31-0.05USD/shares90

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2019-10-01 to 2019-12-310.1USD/shares92
2019-01-01 to 2019-12-310.05USD/shares365
2019-07-01 to 2019-09-30-0.01USD/shares92
2019-04-01 to 2019-06-30-0.02USD/shares91
2019-01-01 to 2019-03-31-0.02USD/shares90
2018-10-01 to 2018-12-31-0.02USD/shares92
2018-01-01 to 2018-12-31-0.03USD/shares365
2018-07-01 to 2018-09-300.03USD/shares92
2018-04-01 to 2018-06-30-0.02USD/shares91
2018-01-01 to 2018-03-31-0.02USD/shares90
2017-10-01 to 2017-12-31-0.04USD/shares92
2017-01-01 to 2017-12-31-0.13USD/shares365
2017-07-01 to 2017-09-30-0.03USD/shares92
2017-04-01 to 2017-06-30-0.02USD/shares91
2017-01-01 to 2017-03-31-0.05USD/shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2019-12-312,640USD
At 2019-09-3012,988USD
At 2019-06-3028,930USD
At 2019-03-3144,873USD
At 2018-12-3160,815USD
At 2018-09-3076,757USD
At 2018-06-3092,133USD
At 2018-03-31108,075USD
At 2017-12-31124,017USD
At 2017-09-30139,959USD
At 2017-06-30155,902USD
At 2017-03-31146,591USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-01-01 to 2017-12-31803USD365

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-10-01 to 2019-12-31-177,706USD92
2019-01-01 to 2019-12-31-837,002USD365
2019-07-01 to 2019-09-30-175,490USD92
2019-04-01 to 2019-06-30-240,828USD91
2019-01-01 to 2019-03-31-242,978USD90
2018-10-01 to 2018-12-31-261,434USD92
2018-01-01 to 2018-12-31-513,230USD365
2018-07-01 to 2018-09-30376,279USD92
2018-04-01 to 2018-06-30-330,678USD91
2018-01-01 to 2018-03-31-297,397USD90
2017-10-01 to 2017-12-31-554,945USD92
2017-01-01 to 2017-12-31-2,076,285USD365
2017-07-01 to 2017-09-30-412,444USD92
2017-04-01 to 2017-06-30-455,569USD91
2017-01-01 to 2017-03-31-653,327USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-12-3132,795USD
At 2019-09-3054,021USD
At 2019-06-3012,861USD
At 2019-03-3118,065USD
At 2018-12-31101,080USD
At 2018-09-30199,718USD
At 2018-06-3048,348USD
At 2018-03-3112,708USD
At 2017-12-3173,989USD
At 2017-09-3018,664USD
At 2017-06-3052,691USD
At 2017-03-31215,571USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2019-01-01 to 2019-12-3143,787USD365
2018-01-01 to 2018-12-3139,514USD365
2017-01-01 to 2017-12-3120,219USD365

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-12-314,762,989USD
At 2019-09-306,230,401USD
At 2019-06-306,175,121USD
At 2019-03-315,944,935USD
At 2018-12-315,790,786USD
At 2018-09-305,634,045USD
At 2018-06-305,861,727USD
At 2018-03-315,582,253USD
At 2017-12-315,355,655USD
At 2017-09-304,972,262USD
At 2017-06-304,600,648USD
At 2017-03-314,311,992USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2019-12-31967,126USD
At 2018-12-311,857,951USD
At 2017-12-311,870,215USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-01-01 to 2019-12-31837,002USD365
2018-01-01 to 2018-12-311,163,230USD365
2017-01-01 to 2017-12-312,126,285USD365

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2019-10-01 to 2019-12-31119,430USD92
2019-01-01 to 2019-12-31593,549USD365
2019-07-01 to 2019-09-30114,047USD92
2019-04-01 to 2019-06-30180,473USD91
2019-01-01 to 2019-03-31179,599USD90
2018-10-01 to 2018-12-31198,298USD92
2018-01-01 to 2018-12-31907,836USD365
2018-07-01 to 2018-09-30207,279USD92
2018-04-01 to 2018-06-30267,629USD91
2018-01-01 to 2018-03-31234,630USD90
2017-10-01 to 2017-12-31518,184USD92
2017-01-01 to 2017-12-311,781,309USD365
2017-07-01 to 2017-09-30351,173USD92
2017-04-01 to 2017-06-30389,387USD91
2017-01-01 to 2017-03-31522,565USD90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-10-01 to 2019-12-3158,276USD92
2019-01-01 to 2019-12-31243,453USD365
2019-07-01 to 2019-09-3061,443USD92
2019-04-01 to 2019-06-3060,355USD91
2019-01-01 to 2019-03-3163,379USD90
2018-10-01 to 2018-12-3163,136USD92
2018-01-01 to 2018-12-31255,394USD365
2018-07-01 to 2018-09-3066,442USD92
2018-04-01 to 2018-06-3063,049USD91
2018-01-01 to 2018-03-3162,767USD90
2017-10-01 to 2017-12-3186,761USD92
2017-01-01 to 2017-12-31344,976USD365
2017-07-01 to 2017-09-3061,271USD92
2017-04-01 to 2017-06-3066,182USD91
2017-01-01 to 2017-03-31130,762USD90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-12-3114,489,399shares
At 2018-12-3114,433,843shares
At 2017-12-3114,373,544shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-12-31114,020,581USD
At 2018-12-31114,020,586USD
At 2017-12-31113,940,592USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2019-12-31-4,849,763USD
At 2018-12-31-5,628,891USD
At 2017-12-31-5,156,147USD
At 2016-12-31-3,289,669USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2019-12-31203,605USD
At 2018-12-31203,605USD
At 2017-12-31203,605USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2019-12-31200,965USD
At 2018-12-31142,790USD
At 2017-12-3179,588USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2017-12-3111,767USD
At 2017-09-3011,767USD
At 2017-06-3011,766USD
At 2017-03-3111,766USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2019-12-312,796,689USD
At 2018-12-312,856,634USD
At 2017-12-312,244,517USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2019-12-3132,395USD
At 2018-12-3118,965USD
At 2017-12-3125,000USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2019-10-01 to 2019-12-311,434,024USD92
2019-01-01 to 2019-12-31779,128USD365
2019-07-01 to 2019-09-30-150,457USD92
2019-04-01 to 2019-06-30-251,332USD91
2019-01-01 to 2019-03-31-253,107USD90
2018-10-01 to 2018-12-31-271,321USD92
2018-01-01 to 2018-12-31-552,744USD365
2018-07-01 to 2018-09-30363,676USD92
2018-04-01 to 2018-06-30-339,775USD91
2018-01-01 to 2018-03-31-305,324USD90
2017-10-01 to 2017-12-31-562,085USD92
2017-01-01 to 2017-12-31-2,096,504USD365
2017-07-01 to 2017-09-30-418,858USD92
2017-04-01 to 2017-06-30-460,278USD91
2017-01-01 to 2017-03-31-655,283USD90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2019-01-01 to 2019-12-3158,175USD365
2018-01-01 to 2018-12-3163,202USD365
2017-01-01 to 2017-12-3166,087USD365

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2019-10-01 to 2019-12-311,611,730USD92
2019-01-01 to 2019-12-311,616,130USD365
2019-07-01 to 2019-09-3025,033USD92
2019-04-01 to 2019-06-30-10,504USD91
2019-01-01 to 2019-03-31-10,129USD90
2018-10-01 to 2018-12-31-9,887USD92
2018-01-01 to 2018-12-31-39,514USD365
2018-07-01 to 2018-09-30-12,603USD92
2018-04-01 to 2018-06-30-9,097USD91
2018-01-01 to 2018-03-31-7,927USD90
2017-10-01 to 2017-12-31-7,140USD92
2017-01-01 to 2017-12-31-20,219USD365
2017-07-01 to 2017-09-30-6,414USD92
2017-04-01 to 2017-06-30-4,709USD91
2017-01-01 to 2017-03-31-1,956USD90

Deferred income tax expense or benefit

The deferred portion of income tax expense or benefit, arising from timing differences. It is not tax paid in the period.

PeriodValueUnitDays
2017-01-01 to 2017-12-3114,500,000USD365

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2019-01-01 to 2019-12-318,716USD365
2018-01-01 to 2018-12-3110,269USD365
2017-01-01 to 2017-12-318,578USD365

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2019-01-01 to 2019-12-3177,511USD365
2018-01-01 to 2018-12-31-12,263USD365
2017-01-01 to 2017-12-31197,151USD365

Inspect the source

Entity
Gene Biotherapeutics, Inc. / CIK 0000772320
Captured
SEC response SHA-256
e91552cfabee8416dbcf0b8fa878884f925550f547c9b83f09dd1693554ad83d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000772320.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))